Ampio Pharmaceuticals, Inc. (AMPE)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
0.75-0.06 (-7.62%)
At close: 4:02 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.82
Bid0.75 x 500
Ask1.07 x 1000
Day's Range0.75 - 0.85
52wk Range0.75 - 4.32
1y Target EstN/A
Market Cap43M
P/E Ratio (ttm)-1.34
Avg Vol (3m)853,814
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire20 days ago

    Ampio Reports Peer-Reviewed Publication on the Potential use of Ampion™ in New Clinical Indications

    Dr. David Bar-Or, Ampio's Chief Scientific Officer, explained: "We reported an important positive effect of Ampion™ on stabilization of alpha tubulin (a cytoskeleton protein involved in trafficking molecules inside the cell and important in controlling vascular permeability) in retinal endothelial cells and described the mechanism of action of Ampion™ and a resulting decrease in leakage of fluid through these cells which normally line the interior of blood vessels in the retina.

  • PR Newswire29 days ago

    Ampio Reports Additional Peer-Reviewed Publication on Ampion™

    ENGLEWOOD, Colo., Aug. 30, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today publication in the peer-reviewed journal Biochemistry and Biophysics Reports that further describes the modes of action (MOA) of Ampion™ in the treatment of Osteoarthritis. Dr. David Bar-Or, Ampio's Chief Science Officer, noted, "This manuscript reports that in the presence of either IL-1β or TNFα, LMWF-5A (Ampion™) increased the expression of both COX2 mRNA and protein, and this increase was significant compared to that observed with IL-1β- or TNFα-stimulated, saline-treated cells.

  • PR Newswirelast month

    Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering

    ENGLEWOOD, Colo., Aug. 29, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has entered into a securities purchase agreement with an institutional investor providing for the registered sale of 5,000,000 shares of common stock and accompanying warrants to purchase up to 5,000,000 shares of common stock with an exercise price of $1.00 per share, at a combined purchase price of $0.75 per share and accompanying warrant. The Company intends to use the net proceeds from this offering for general corporate purposes as well as advancing the BLA for Ampion™ and its future clinical trials. Financial West Group is acting as the exclusive placement agent for the offering.